Advertisement
Research Article

The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland

  • Simon N Stacey mail,

    To whom correspondence should be addressed. E-mail: simon.stacey@decode.is (SNS); E-mail: kari.stefansson@decode.is (KS)

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Patrick Sulem,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Oskar T Johannsson,

    Affiliation: Department of Oncology, National University Hospital, Reykjavik, Iceland

    X
  • Agnar Helgason,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Julius Gudmundsson,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Jelena P Kostic,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Kristleifur Kristjansson,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Thora Jonsdottir,

    Affiliation: Cancer Centre, National University Hospital, Reykjavik, Iceland

    X
  • Helgi Sigurdsson,

    Affiliations: Department of Oncology, National University Hospital, Reykjavik, Iceland, Cancer Centre, National University Hospital, Reykjavik, Iceland

    X
  • Jon Hrafnkelsson,

    Affiliation: Department of Oncology, National University Hospital, Reykjavik, Iceland

    X
  • Jakob Johannsson,

    Affiliation: Department of Oncology, National University Hospital, Reykjavik, Iceland

    X
  • Thorarinn Sveinsson,

    Affiliations: Department of Oncology, National University Hospital, Reykjavik, Iceland, Department of Radiation Physics, National University Hospital, Reykjavik, Iceland

    X
  • Gardar Myrdal,

    Affiliation: Department of Radiation Physics, National University Hospital, Reykjavik, Iceland

    X
  • Hlynur Niels Grimsson,

    Affiliation: Department of Oncology, National University Hospital, Reykjavik, Iceland

    X
  • Jon T Bergthorsson,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Laufey T Amundadottir,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Jeffrey R Gulcher,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Unnur Thorsteinsdottir,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Augustine Kong,

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Kari Stefansson mail

    To whom correspondence should be addressed. E-mail: simon.stacey@decode.is (SNS); E-mail: kari.stefansson@decode.is (KS)

    Affiliation: deCODE Genetics, Reykjavik, Iceland

    X
  • Published: June 20, 2006
  • DOI: 10.1371/journal.pmed.0030217

About the Authors

Simon N Stacey, Patrick Sulem, Agnar Helgason, Julius Gudmundsson, Jelena P Kostic, Kristleifur Kristjansson, Jon T Bergthorsson, Laufey T Amundadottir, Jeffrey R Gulcher, Unnur Thorsteinsdottir, Augustine Kong, Kari Stefansson
deCODE Genetics, Reykjavik, Iceland
Oskar T Johannsson, Helgi Sigurdsson, Jon Hrafnkelsson, Jakob Johannsson, Thorarinn Sveinsson, Hlynur Niels Grimsson
Department of Oncology, National University Hospital, Reykjavik, Iceland
Thora Jonsdottir, Helgi Sigurdsson
Cancer Centre, National University Hospital, Reykjavik, Iceland
Thorarinn Sveinsson, Gardar Myrdal
Department of Radiation Physics, National University Hospital, Reykjavik, Iceland

Corresponding Authors

Competing Interests

SNS, PS, AH, JG, JPK, KK, JTB, LTA, JRG, UT, AK, and KS are employees and/or have stock or equity interests in deCODE Genetics.

Author Contributions

SNS, PS, OTJ, JG, KK, JH, HNG, LTA, UT, and KS designed the study. SNS, PS, AH, JG, JPK, JTB, UT, and AK analyzed the data. SNS, OTJ, HS, JH, JJ, and TS enrolled patients. PS, OTJ, JPK, KK, TJ, HS, HG, and AK collected data or did experiments for the study. GM participated in discussion of the project and the results. SNS, PS, OTJ, AH, JG, HS, JH, JJ, JTB, LTA, JRG, UT, and KS contributed to writing the paper.